Picture yourself on a hospital data team. A clinician has forwarded you a vendor blog post about agentic AI in cancer care and asked a simple question: if we let agents near patient data, what would they actually run on, and can we trust the claims? You have an afternoon to answer.
The post is from Snowflake. Its healthcare CTO, Murali Gandhirajan, walks the cancer journey in five stages: discovery, screening, diagnosis, treatment and survivorship. His argument is that "all five bottlenecks trace back to the same root cause: There is no unified data foundation that can reason across the continuum." The scenario that stays with you is a single data event. An agent "receives a sequencing result, compares it with similar patient profiles, identifies open trials, models feasibility and prepares a tumor board summary."
Before you repeat any numbers to your clinician, you sort them into two piles. The industry figures are cited to outside sources: oncology drug attrition above 95% and $50 billion to $60 billion a year on failed trials, from a 2023 JAMA Network Open study, plus 21.6% more breast cancers found by an AI-supported screening workflow. The customer figures are vendor case studies. AstraZeneca is said to have cut data product development from six months with 16 engineers to four days with two, with more than 118 data products and more than $10 million in savings. Zelis is said to ingest from more than 40 sources through Openflow and run more than 20 production agents. You read those as Snowflake's numbers, not independent findings.
What survives that sorting is the governance line, and it is the right one for protected health information: "auditability, access controls, agent guardrails and clear rules for when to keep humans in the loop are mission critical."
So you turn to the APIs.io catalog to see whether the record agrees. Here it does. The Snowflake provider page lists 49 API pages, and the ones the story's agents would run on are all there: the Cortex Agents API, the Cortex Analyst API, the Cortex Search Service API and the Cortex Inference API. The Grant API and Role API are listed too, and they carry the access controls the post calls mission critical. The Snowflake agentic access profile counts 408 operations, 276 of them acting and 14 human-in-the-loop. The catalog description records an account-hosted MCP server exposing Cortex tools "under Snowflake RBAC." One gap shows up: Openflow, which the Zelis example depends on, has no API page of its own.
The scores tell you where the strength sits. Snowflake scores 81.2 on the Kin Score, in the exemplar band, led by access clarity at 92.1 and developer ergonomics at 80.4. Contract governance is the weakest facet at 45.5. Agent Readiness is 45.6, agent-native, with MCP server, idempotency, reversibility and agent skills lit.
Then the turn that matters for your afternoon. Several agent-readiness dimensions are not lit: consent identity, dry-run mode, protected resource metadata and dynamic client registration. For a post about agents acting on patient data, consent identity is the one to watch. The human-in-the-loop rule Snowflake describes is real in its operations, and the record does not yet show how a patient's consent travels with an agent's request.
You now have an answer you can give. The agent building blocks and the access controls are documented, and the governance claim is backed by what the catalog lists. The savings and speed figures belong to Snowflake and should stay labeled that way. And the open question for your own review is consent: ask how it is carried, because the record does not say.
Read the original: https://apis.io/2026/10/27/snowflake-oncology-agents-stand-on-one-of-the-catalogs-strongest-records/